Bond AmgenX 5.25% ( US031162DQ06 ) in USD
| Issuer | AmgenX |
| Market price | |
| Country | United States
|
| ISIN code |
US031162DQ06 ( in USD )
|
| Interest rate | 5.25% per year ( payment 2 times a year) |
| Maturity | 02/03/2030 |
|
Prospectus brochure in PDF format is unavailable at this time We will provide it as soon as possible |
|
| Minimal amount | 2 000 USD |
| Total amount | 2 750 000 000 USD |
| Cusip | 031162DQ0 |
| Standard & Poor's ( S&P ) rating | BBB+ ( Lower medium grade - Investment-grade ) |
| Moody's rating | Baa1 ( Lower medium grade - Investment-grade ) |
| Next Coupon | 02/03/2026 ( In 73 days ) |
| Detailed description |
Amgen is a leading biotechnology company focused on developing and delivering innovative therapies for serious illnesses in areas such as oncology, cardiovascular disease, and inflammation. An investment-grade bond issued by Amgen, a prominent American biotechnology corporation operating from the United States and globally recognized for its focus on discovering, developing, manufacturing, and delivering innovative human therapeutics, is currently a notable offering in the fixed-income market. This particular obligation, bearing the ISIN US031162DQ06 and CUSIP 031162DQ0, offers an annual interest rate of 5.25%, with coupon payments disbursed semi-annually. Denominated in USD, the bond is presently trading on the market at 102.773% of its par value, reflecting current market demand. It represents a component of a substantial total issuance valued at $2.75 billion, with a minimum investment threshold set at $2,000 per purchase, and is set to mature on March 2, 2030. Its credit quality is affirmed by strong investment-grade ratings from leading agencies: Standard & Poor's has assigned a BBB+ rating, while Moody's has provided a Baa1 rating, underscoring Amgen's financial solidity and ability to fulfill its debt commitments. |
Français
Italiano
United States